Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

ESMO gastrointestinal oncology·2026

Same author

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.

ESMO open·2026

Same author

Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial.

ESMO open·2026

Same author

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Frontiers in oncology·2025

Same author

Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.

ESMO open·2024

Same journal

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

ESMO open·2026

Same journal

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

ESMO open·2026

Same journal

ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer.

ESMO open·2026

Same journal

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026

Same journal

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.

ESMO open·2026

Same journal

Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years.

ESMO open·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 14, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

How I treat diffuse large B-cell lymphoma.

T Melchardt¹, A Egle¹, R Greil¹

¹IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria.

|January 12, 2023

Summary

This summary is machine-generated.

This study outlines a risk-stratified approach to first-line diffuse large B-cell lymphoma (DLBCL) treatment. It highlights abbreviated chemoimmunotherapy for low-risk patients and new combination therapies for high-risk DLBCL.

Keywords:

CAR-T cells diffuse large B-cell lymphoma interim PET polatuzumab vedotin

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Aug 14, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Oncology
Hematology
Clinical Medicine

Background:

Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
Current first-line treatment involves chemoimmunotherapy with curative intent.
Prognostic tools and novel agents are refining treatment strategies.

Purpose of the Study:

To summarize a risk-adapted approach for first-line DLBCL management.
To address challenges in clinical practice, including specific patient subgroups.
To integrate novel therapies and prognostic information into treatment decisions.

Main Methods:

Risk stratification based on prognostic factors.
Review of treatment guidelines and clinical practice.
Consideration of interim positron emission tomography (PET) response.
Evaluation of novel agents like polatuzumab vedotin.

Main Results:

Abbreviated chemoimmunotherapy is recommended for low-risk DLBCL patients with negative interim PET.
Polatuzumab vedotin combination therapy is a new option for high-risk DLBCL.
Specific management strategies are discussed for CNS involvement, leg-type lymphoma, and comorbidities.

Conclusions:

A personalized, risk-stratified approach optimizes DLBCL treatment outcomes.
Novel agents and prognostic tools enhance therapeutic options for DLBCL patients.
Addressing specific clinical challenges is crucial for comprehensive DLBCL care.